2nd Quarter - Report

BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.

Firm
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Creating Hope Reauthorization Act of 2024 - H.R. 7384 Innovation in Pediatric Drugs Act - H.R. 6664 March-in/Bayh-Dole Act Orphan drug policies

LobbyistCovered position, as disclosed
AMANDA MALAKOFF —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7384 (118th), H.R. 6664 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.